共 52 条
[1]
Lavanchy D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, J Viral Hepat, 11, pp. 97-107, (2004)
[2]
Gish R.G., Gadano A.C., Chronic hepatitis B: Current epidemiology in the Americas and implications for management, J Viral Hepat, (2006)
[3]
Ganem D., Prince A.M., Hepatitis B virus infection - Natural history and clinical consequences, N Engl J Med, 350, pp. 1118-1129, (2004)
[4]
(2006)
[5]
Dienstag J.L., Cianciara J., Karayalcin S., Et al., Durability of serologic response after lainivadine treatment of chronic hepatitis B, Hepatology, 37, pp. 748-755, (2003)
[6]
Fung S.K., Wong F., Hussain M., Lok A.S., Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B, J Viral Hepat, 11, pp. 432-438, (2004)
[7]
Bartholomeusz A., Locarnini S.A., Antiviral drug resistance: Clinical consequences and molecular aspects, Semin Liv Dis, pp. 162-170, (2006)
[8]
Fung S.K., Andreone P., Han S.H., Et al., Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation, J Hepatol, 43, pp. 937-943, (2005)
[9]
Hoofnagle J.H., DiBisceglie A.M., The treatment of chronic viral hepatitis, N Engl J Med, 336, pp. 347-356, (1997)
[10]
Cihlar T., Lin D.C., Pritchard J.B., Et al., The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1, Mol Pharmacol, 56, pp. 570-580, (1999)